ALK7 binding proteins and uses thereof

US10501547B2 · kind B2 · utility

Assignees

• Acceleron Pharma Inc. · US
• Adimab, LLC · US

Inventors

• John Knopf · Carlisle, US
• Jonathan Belk · Lebanon, US
• Nathan J. Sharkey · Lebanon, US
• Ravindra Kumar · Cambridge, US
• Asya Grinberg · Lexington, US
• Dianne Sako · Medford, US
• Roselyne Castonguay · Malden, US
• Yossi Dagon · Cambridge, US

Key dates

• Filing date: Apr 21, 2017
• Grant date: Dec 10, 2019
• Expiry date: Jul 1, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.